Silexion’s SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.
Silexion Therapeutics’ Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer
